Zydus Lifesciences Plans To Launch Injection For Diabetes And Obesity On Day 1 Of Patent Expiry

DCGI had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity.